To adopt an efficient approach of identifying rare variants possibly related to Hirschsprung disease (HSCR), a pilot study was set up to evaluate the performance of a newly designed protocol for next generation targeted resquencing. In total 20 Chinese HSCR patients and 20 Chinese sexmatched individuals with no HSCR were included, for which coding sequences (CDS) of 62 genes known to be in signaling pathways relevant to enteric nervous system (ENS) development were selected for capture and sequencing. Blood DNAs from eight pools of five cases or controls were enriched by PCR-basedRaindance technology (RDT) and then sequenced on a 454 FLX platform. As technical validation, five patients from case Pool-3 were also independently enriched by RDT, indexed with barcode and sequenced with sufficient coverage. Assessment for CDS single nucleotide variants showed DNA pooling performed well (specificity/sensitivity at98.4%/83.7%) at the common variant level; but relatively worse (specificity/sensitivity at 65.5%/61.3%) at the rare variant level. Further Sanger sequencing only validated five out of 12 rare damaging variants likely involved in HSCR.
INTRODUCTION
Targeted resequencing is a direct approach to pinpoint the causal or associated rare variants/mutations (RVs) in one or a few given genes (Rehm, 2013) . The combination of PCR-based enrichment (for targeted sequence regions) and first-generation sequencing platforms (Sanger sequencing on ABI 3730 sequencer) is very efficient and is considered as the gold standard method for validating DNA mutations. However, due to the high cost, large-scale Sanger sequencing is not applicable to the screening of patients affected by multi-genic diseases where the number of candidate genes to be screened for RVs may easily be larger than 10.Next generation sequencing and microarray-based enrichment technologies (multiplex capture)offer not only high coverage of sequence reads, but also good capture specificity for targeted DNA regions withinaffordable research budgets (Summerer et al., 2009 ). This combination, next generation targeted resequencing, has been adopted for clinical genetic testing ofhereditary cancers, cardiac diseases and sensory disorders where the genetic mechanisms are relatively well understood (Rehm, 2013) . Meanwhile, it also enables population-based research that aims to further explore the roles of RVs in a batch of candidate genes identified by previous linkage or association studies.
Hirschsprung disease (HSCR, aganglionicmegacolon) is a complex genetic disorder of the enteric nervous system (ENS) characterized by the absence of enteric neurons along a variable length of the intestine. This is attributed to a failure in the migration of the enteric neuronprecursors, the Targeted resequencingand DNA pooling 5 neural crest cells (NCCs) (Torfs, 2004 , Amiel et al., 2008 . The receptor tyrosine kinase gene (RET) is the major HSCR gene and its expression is crucial for the development of the enteric ganglia and hence the ENS (Amiel & Lyonnet, 2001) . RVs in the coding sequence (CDS) of RET account for up to 50% of the familial cases and between 10%-20% of the sporadic cases. In addition to CDS mutations, RET common variants (single nucleotide polymorphisms -SNPs) are strongly associated with HSCR (Emison et al., 2005) . Yet, despite the importance of RET, additional genes (acting either in conjunction or independently from RET) are necessary to explain not only the disease incidence but also its complex pattern of inheritance. Other HSCR genes identified so far mainly code for protein members of inter-related signaling pathways involved in the ENS development: endothelin receptor B (EDNRB), the transcriptional regulator SOX10and the NRG1/ERBB2signaling pathway gene (Hofstra et al., 1999 , Heanue & Pachnis, 2007 , Garcia-Barcelo et al., 2009 .CDS mutations in genes other than RET thus far only account for 7% of the cases, however the unexplained phenotypic variance in sporadic HSCR cases is still very high (>80%) (Gui et al., 2013) .This suggests that variations in other genes involved in ENS development are likely to contribute to the manifestation of the phenotype (Heanue & Pachnis, 2007) . Nevertheless, not many of the known or candidate genes have been systematically screened in HSCR patients aside from RET. Hence it is promising to adopt multiplex capture and parallel sequencing to efficiently identify rare variants residing in genemembers of these signaling pathways relevant to processes that, when altered, give rise to diseases.
Targeted sequencing on complex diseases has previously shown that a population-based design involving > 1000 cases/controls is always required (Wu et al., 2011) . However, a few technical issues need to be handled before this large-scale sequencing project proceeds on HSCR. This includes selection of candidate genes, design of capture kits, and choice of multiplexing sequencing, among others (Mertes et al., 2011) . Therefore, we set up a pilot study in which a new strategy of NGS-based target resequencing was conducted on a relatively small sample of HSCR patients and normal controls. Evaluation of this strategy would provide technical guidance on future targeted resequencing studies on complex diseases including HSCR.
MATERIALS AND METHODS

Sample collection
HSCR diagnosis was based on histological examination of either biopsy or surgical resection material for absence of enteric plexuses. Patients were also fully characterized and a pro-formaquestionarewas provided for each patient. In total 20 HSCR patients (16 males and fourfemales) were included in this pilot study. As controls, we included 20 Chinese individuals (16 males and four females) with no HSCR. Adult individuals gave written informed consent and for Targeted resequencingand DNA pooling 7 minors, written informed consent was obtained from their parents. The study was approved by the institutional review board of The University of Hong Kong together with the Hospital Authority (IRB:UW09-360).
Gene selection
Candidate genes were selected according to the evidence oftheir involvement in ENS development (provided by either the phenotype presented by mouse models, in vitro data,orin silico data). All of the14 genes known to cause HSCR in human newborns and ENS failure in the embryonic mouse (Table 1) werecompulsorily included, while the other 48 genes (Table S1) were selected according to the following reasons: 1) key members in the same signaling pathway with know HSCR genes; 2) genes with suggestive association with HSCR in our previous GWAS study (Garcia-Barcelo et al., 2009 ); 3) supported by murineor functional studies as outlinedin Table S1 .
DNA pooling
To minimize the cost, a protocol of DNA pooling that was previously recommended in large-scale genotyping studies was adopted (Sham et al., 2002) . In detail, DNA wasextracted fromperipheral blood samples (20 cases and 20 controls) and was fragmented into 2~4Kb fragments by sonication. DNA concentrations were measured by picogreen reagent in triplicate and were normalized to 10ng/μl.These genomic DNA samples were then arranged into pools with five cases or controls each in order to maximize the usage of the multiplex design, given the length of gene locus and PCR amplification. In overall, eight DNA templates (pool of DNA from five individuals and PCR reagents) were prepared,
Enrichment and capture
RainDance Technology (RDT 1000; RainDance Technologies, Lexington, MA, USA) was chosen to conduct multiplex capture for targeted regions (all exons + 2kb of 5' and 3' flanking UTR) ofthe 62 candidate genes. Basically, RDT allows us to PCR-amplify up to 4000 selected 500bp length sequences per DNA template by providing a custom-made pooled primer-pair library (http://www.raindancetechnologies.com). In brief, aliquoted primers were loaded on the RDT 1000 enrichment chip along with a conventional PCR mix and 3-4μg of fractionated (to facilitate primer annealing) pooled-genomic DNA. During this process, each primer pair droplet merged with a droplet that contained genomic DNA, and PCR reagents. Approximately 1.5 million droplets were collected in a 0.2mL single tube and were directly PCR amplified. Amplification products were recovered by breaking the emulsion followed by purification using a MiniElute PCR Purification Kit (QIAGEN, QIAGEN Hong Kong Pte. Limited, Hong Kong).The whole strategy isshown in Figure S1 .
Sequencing
During preparation of the sequencing library, purified PCR products generated in the previous steps were ligated to two distinct oligonucleotide adapters to provide priming sites for subsequent amplification and sequencing (Shendure & Ji, 2008 , Rothberg & Leamon, 2008 .The templates were amplified and immobilized by compartmentalizing individual template molecules and 28-m DNA capture beads within droplets of an emulsion. PCR reactions conducted inside the droplets amplified the template molecules and complementary primers covalently attached to the DNA capture beads immobilizedthe template. Template-covered DNA capture beads were loaded into individual wells etched into the surface of a fiber-optic slide.The sequencing process is the same as that used in pyrosequencing (454 Genome Sequencer FLX, Roche Inc., Branford, USA). Raw sequence reads were handled by the GS Data Analysis Software package accompanied by the GSFLXsystem, using gsMapper for alignment (human reference genome 19) and Newbler for variant calling (Roche Inc.).
Only those single nucleotide variants (SNVs) with relatively high quality annotations (total read depth > 40, alternative allele > 3, and phred score > 20) were included for downstream analysis.
Technical validation
To evaluate the proposed protocol at detecting true single nucleotide variants, one pool of samples (five HSCR patients in case pool-3) was individually sequenced with high coverage (>300×).This pool was selected since all those five patients were also genotyped by Affymetrix 500K in our previous genome-wide association study (Garcia-Barcelo et al., 2009) . The same RainDancetechnology was used to capture and enrich coding sequences of 62 candidate genes; however, DNA template was prepared using independent index primersfor each individual without pooling and was then sequenced on an IlluminaGAIIX platform (Illumina, San Diego,USA). Raw reads in fastq format were exported and aligned to human reference genome build 19 with BWA software (Li & Homer, 2010 ). The GATK pipeline was then used to preprocess each sequence (re-alignment, recalibration) and to call SNVs on multiple samples together (DePristo et al., 2011) .Only SNVs with total read depth > 8, allelic ratio for alternative allele > 0.25, and Phred score > 20) were reported.
Variant assessment
All genetic variants were annotated by KGGSeq and then classified into noncoding or coding (defined by Refgene), common or rare (minor allele frequency < 0.01 in dbSNP137), and damaging or non-damaging by Polyphen2 (Li et al., 2012) . Rare damaging variants detected in pool-3 patients were validated by Sanger sequencing. The sensitivity and specificity of detecting two types of variants (common and rare) by DNA pooling were calculated from the overlapped or non-overlapped counts between variants found in one sequenced pool and variants found in all individually sequenced patients.
Rare variant prioritization
In order to pinpoint the most deleterious mutations that separate cases from controls, a step-by-step filtering was conducted on all variants found in different pools according to MAFreported in public databases (1000 Genomes Project, dbSNP137 and NHLBI Exome sequencing project), their functional impact and variant/gene recurrence across pools. Burden analysis (binomial test for the variant count difference between cases and controls) was performed on variants or genes retained at each level (Zhao et al., 2012) . A final set of rare damaging variants from genes present in case pools only were sent for validation using Sanger sequencing.
RESULTS
Coverage (average read depth per base on targeted regions) and target specificity (unique reads on targets over total unique reads) were used to evaluate read-level performance. As shown in Table 2 , the average read depth across the target regions for RDT was above 80×across eight pools, with range from 54.21× to 93.53×. In addition, the target specificity was 74.18% forRDT, while 74.12% of the RDT targeted bases were covered with depth >=40. In terms of variant calling, our protocol detected 943 raw SNVs (149 within CDS, 13.6%) per pool. Only those SNVs located in CDS regions were assessed. In overall, 89.5% CDS SNVs were also found in dbSNP137 (Table 2 ).
Variants detected in the pool-3 sample were compared between pooled sequencing and individual indexed sequencing on the same five cases. The validity of using individual sequence as technical validation was indicated by their read depth coverage (>300×), dbSNP137 coverage (~92%) and concordance with GWAS array (>95%) ( Table 3 ). In general, the specificity and sensitivity for pooled sequencing were 92% (139 out of 151) and 79.4%(139 out of 175) respectively. When classified into common or rare variants according to dbSNP137 (MAF at 0.01), the specificity and sensitivity were98.4%/83.3.7%, or 65.5%/61.3% respectively (Table 4) . This difference was verified by using small set common variants overlapped with the SNP array, and rare damaging variants validated by Sanger sequencing. By pooled sequencing, 11 out of 13 SNPs were found and all of them matched the minor/major allele by counting sequence reads covering reference or alternative alleles. On the other hand, six out of 10 rare damaging variants found by pooled sequencing were verified by Sanger, compared to seven out of eight variants for individual sequencing.
Among all eight pools, 366 coding sequence SNVsin20 different HSCR cases and 20 healthy controls were detected by our protocol. The distribution of variant count in cases and controls is shown in Table 5 , as stratified by allele frequency and deleteriousness. No significant burden was found for mutation load at any level between cases and controls (p-value >0.05; Table 5 ). With regard to genes carrying rare damaging mutations, thesecould be classified into case-only, case-control and control-only by the presence of at least one mutation. None of these, however,were shown to have a significant burden in HSCR cases versus healthy controls(data not shown).
Nevertheless, genes uniquely mutated in patients only may be considered as functional hits for further analysis. Therefore 12SNVscontained in these genes were selected for validation by Sanger sequencing. Finally,fiveout of these 12 variants were successfully validated (data not shown);at the phenotype level, only fourout of 20 patients (oneshort male, oneshort female and twolong female cases; 20%) carried at least one validated mutation with high functional impact.
DISCUSSION
In our current study,we designed a protocol combining DNA pooling, RDT multiplex capture and next generation sequencing together for targeted resequencing research. Its performance was carefully evaluated through the application on an HSCR case/control dataset. The idea of DNA pooling was widely applied for studying disease risk variants in large-scale population samples (Sham et al., 2002 ). An efficient association can be done by comparing minor allele frequency between case pools and control pools, without knowing the exact individual genotype. This was supported by our pooled sequencing for common variants, for whichthe presence of a variant can be detected by counting reads harboring reference alleles and alternative alleles.However, this approach did not seem reasonable when examining rare variants, as revealed by the high false positive rate and high false negative rate found in our study.
It is true that barcoding individual samples in targeted sequencing would be a better approach for detecting rare variants (Cummings et al., 2010) . However, it will be much more laborious and expensive than DNA pooling in a large-scale population-based study. From the perspective of other technologies besides DNA pooling in our protocol, on-target reads showed capture specificity for RDT was relatively better than hybridization-based capture on the same 62 candidate genes (our own published data, the Centre for Genomic Sciences, the University of Hong Kong), which may be ascribed to its higher specificity for pseudo-genes (including other paralogous sequences) and total targeted regions < 1M base pairs (Mondal et al., 2011) . Given the advantage of multiplex capture technology been considered, the current drawback could be overcome by improving the performance of the NGS sequencer in terms of read accuracy together with cost-efficiency. It is sensible to envisage the potential of DNA pooling as sequencing technology advances.
Because of the intricate ways in which biological processes operate, rare (especially damaging) variants are likely to differ among individuals with the same disease, thus accounting for phenotypic variability. Of note is the fact that RVs identified in HSCR patients happen to belong to pathways involved in ENS development (Heanue & Pachnis, 2007 , Heanue & Pachnis, 2006 . However, we were not able to prioritize genes by binomial tests mainly because of limited power given the small sample size, low frequency of effective variants and relatively low specificity and sensitivity of the technologies (Kiezun et al., 2012) . A simplified estimation on variant level indicated that 600 case-control pairs is needed to detect RVs with odds ratio (OR) above 2 and minor allele frequency above 1% (supplementary Figure 2) . To boost power of detecting more rare variants with moderate effect size (OR <2), gene-wise burden tests should be adopted (Bansal et al., 2010) .
While it is true that RVs need not always be in CDSs and that RVs may include short insertion/deletions (Indels) and longer structural variations (copy number variations, translocations), further investigation on other types of rare variants in candidate genes and whole genomic regions (exome sequencing or whole genome sequencing)are necessary to better explain our HSCR patients not carrying rare damaging SNVs. Full genomic profiles would also give an opportunity to later risk prediction that integrate both common risk variants (RET and NRG1) and rare risk mutations. In addition, replication is always needed since the involvement of a mutated gene/chromosomal region in the disease may only be consolidated by the identification of recurrent mutations or genes in an independent group of patients , Gilissen et al., 2012 , Vissers et al., 2010 .
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SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article: Table S1Genes encoding members of pathways involved in the ENS development As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organised for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors. HSCR. ∫: Mouse Genome Informatics search tool; phenotype refers only to gut/ENS system. *: % of isolated HSCR patients with coding region mutations in these genes, data from (Heanue & Pachnis, 2007 , Amiel & Lyonnet, 2001 , Doray et al., 1998 . -: no patients with isolated HSCR reported. #: Referred from Human disease model (Griseri et al., 2009) or mouse model (Turner et al., 2009 
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